Erschienen in:
01.05.2009
Clinical and Pathologic Evaluation of the Effectiveness of Neoadjuvant Chemoradiation Therapy in Advanced Esophageal Cancer Patients
verfasst von:
Yasunori Akutsu, Hisahiro Matsubara, Kiyohiko Shuto, Masaya Uesato, Mikito Mori, Isamu Hoshino, Toru Shiratori, Yukimasa Miyazawa, Hisao Ito, Takashi Uno
Erschienen in:
World Journal of Surgery
|
Ausgabe 5/2009
Einloggen, um Zugang zu erhalten
Abstract
Background
Chemoradiation therapy (CRT) has the strongest antitumor effect against local tumors of esophageal cancer; however, no standard strategy has yet been established to achieve a clinical complete response (CR) after CRT. The aim of this study was to clarify when a decision can be made to perform further treatment for a clinical CR.
Methods
We evaluated 78 patients that underwent an esophagectomy after neoadjuvant CRT in our department between 1998 and 2007. The study investigated the clinical and pathologic results of neoadjuvant CRT.
Results
Of the 78 cases, 19 (24.3%) were a pathologic CR (Grade 3). Pathologic CR could be estimated in only 3 of 8 clinical CR cases (37.5%). On the other hand, 12 (20.7%) of the 58 clinical partial response (PR) cases achieved pathologic CR. Likewise, 4 cases (36.4%) achieved pathologic CR among the clinical no change/progressive disease (NC/PD) patients.
Conclusions
The clinical evaluation for CRT does not reflect the pathologic effectiveness and, even if clinical CR was achieved, viable cancer cells were still present at the primary site in the majority of the population.